Karyopharm Therapeutics (NASDAQ:KPTI) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note published on Monday morning,Benzinga reports. Royal Bank of Canada currently has a $3.00 price objective on the stock.

A number of other equities analysts have also commented on KPTI. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Performance

KPTI stock opened at $0.59 on Monday. The company has a market capitalization of $73.92 million, a PE ratio of -0.51 and a beta of 0.06. The company’s fifty day moving average price is $0.68 and its 200-day moving average price is $0.77. Karyopharm Therapeutics has a one year low of $0.58 and a one year high of $1.70.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after purchasing an additional 36,922 shares during the period. FMR LLC raised its holdings in Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares during the period. GSA Capital Partners LLP lifted its position in Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after buying an additional 56,613 shares during the period. Finally, AQR Capital Management LLC increased its position in Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares during the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).